Device Trial Radar · NCT05412966
Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence
Last checked: Nov 20, 2026Latest source record: Jan 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Nov 4, 2022
Primary completion
Nov 23, 2022
Study completion Dec 16, 2022
Sponsor
- Lead sponsor
- Pear Therapeutics, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Kaiser Foundation Research Institute; Whitman-Walker Institute, Inc.; National Institute on Drug Abuse (NIDA); Hassman Research Institute, LLC
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess feasibility of an at-home digital therapy designed to support buprenorphine initiation and adherence.
Conditions
- Opioid Use Disorder
Interventions
PEAR-002BDevice
PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
reSET-ODevice
reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PEAR-002B User Satisfaction SurveysTime frame: Week 1
- PEAR-002B Qualitative User Experience InterviewsTime frame: Week 1
- Buprenorphine Initiation SuccessTime frame: Week 1
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hassman Research Institute, LLC
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.